Compare CCU & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCU | KNSA |
|---|---|---|
| Founded | 1850 | 2015 |
| Country | Chile | United Kingdom |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.6B |
| IPO Year | 1992 | 2018 |
| Metric | CCU | KNSA |
|---|---|---|
| Price | $14.84 | $42.45 |
| Analyst Decision | Strong Sell | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $10.00 | ★ $52.33 |
| AVG Volume (30 Days) | 168.3K | ★ 601.6K |
| Earning Date | 02-24-2026 | 02-24-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 5.98 | N/A |
| EPS | 0.38 | ★ 0.47 |
| Revenue | ★ $3,145,028,795.00 | $597,973,000.00 |
| Revenue This Year | $3.14 | $62.63 |
| Revenue Next Year | $4.97 | $31.78 |
| P/E Ratio | ★ $19.46 | $90.40 |
| Revenue Growth | 20.53 | ★ 55.68 |
| 52 Week Low | $11.35 | $18.12 |
| 52 Week High | $15.75 | $44.42 |
| Indicator | CCU | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 74.07 | 55.24 |
| Support Level | $13.83 | $37.02 |
| Resistance Level | $14.46 | $39.74 |
| Average True Range (ATR) | 0.33 | 2.07 |
| MACD | 0.12 | 0.13 |
| Stochastic Oscillator | 93.07 | 81.78 |
United Breweries Co Inc is a multi-category beverage company with operations in Chile, Argentina, Bolivia, Colombia, Paraguay and Uruguay. The company is a player in each one of the beverage categories in which it participates in Chile, including beer, soft drinks, mineral and bottled water, juice, wine, cider and pisco, among others. The Company has three operating segment with respect to its revenues in the geographic areas of commercial activity: Chile; International business and Wine. It generates maximum revenue from Chile.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.